Literature DB >> 20603602

Increased angiogenesis in Cdk4(R24C/R24C):Apc(+/Min) intestinal tumors.

Zahidur R Abedin1, Zhongjie Ma, E Premkumar Reddy.   

Abstract

Cyclin dependent kinase 4 (Cdk4) is a cell cycle regulator involved in early G1 cell cycle progression and has been indirectly implicated in angiogenesis in the Min mouse system, a mouse that harbors a mutation in the Apc gene. Apc(+/Min) mice when crossed with Ink4a/arf-/- mice, exhibited increased angiogenesis of colorectal tumors suggesting that dysregulation of Cdk4 (due to loss of Ink4a-mediated suppression) may contribute to enhanced angiogenesis. To demonstrate a direct role for Cdk4 in angiogenesis, we crossed mice that have an activated Cdk4, Cdk4(R24C/R24C) mice, with Apc(+/Min) mice and examined levels of angiogenesis in intestinal tumors formed. Our results show an increase in the percentage of highly vascularized tumors in Cdk4(R24C/R24C):Apc(Min/+) and Cdk4(+/R24C):Apc(Min/+) mice compared to Cdk4(+/+):Apc(Min/+) mice. In addition immunohistochemical analysis showed an increase in CD-31 staining localized to endothelial cells of Cdk4(R24C/R24C):Apc(Min/+) mouse tumors, supporting the hypothesis of increased vasculature in these tumors. Further analysis showed an increase in the expression of the E2F1 target proteins Vegf-b and Cyclin A in Cdk4(R24C/R24C):Apc(+/Min) intestinal tumors. Together these data suggest that the dysregulated Cdk4 gene plays an important role in angiogenesis during intestinal tumor formation and may in part act via increasing E2F1 target proteins. This is the first report to show that Cdk4 has a direct role in angiogenesis in vivo and may be an important drug target to reduce or prevent angiogenesis during intestinal tumor formation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20603602     DOI: 10.4161/cc.9.12.12055

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  11 in total

1.  Kip3-ing kinetochores clustered.

Authors:  Ryoma Ohi
Journal:  Cell Cycle       Date:  2010-07-01       Impact factor: 4.534

Review 2.  The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer.

Authors:  Ami N Shah; Massimo Cristofanilli
Journal:  Curr Treat Options Oncol       Date:  2017-01

3.  The CDK4/6 inhibitor palbociclib synergizes with irinotecan to promote colorectal cancer cell death under hypoxia.

Authors:  Jun Zhang; Lanlan Zhou; Shuai Zhao; David T Dicker; Wafik S El-Deiry
Journal:  Cell Cycle       Date:  2017-05-09       Impact factor: 4.534

4.  Plasma vascular endothelial growth factor B levels are increased in patients with newly diagnosed type 2 diabetes mellitus and associated with the first phase of glucose-stimulated insulin secretion function of β-cell.

Authors:  J Wu; H Wei; H Qu; Z Feng; J Long; Q Ge; H Deng
Journal:  J Endocrinol Invest       Date:  2017-05-18       Impact factor: 4.256

Review 5.  Progress with palbociclib in breast cancer: latest evidence and clinical considerations.

Authors:  Andrea Rocca; Alessio Schirone; Roberta Maltoni; Sara Bravaccini; Lorenzo Cecconetto; Alberto Farolfi; Giuseppe Bronte; Daniele Andreis
Journal:  Ther Adv Med Oncol       Date:  2016-11-21       Impact factor: 8.168

Review 6.  Mouse models for studying angiogenesis and lymphangiogenesis in cancer.

Authors:  Lauri Eklund; Maija Bry; Kari Alitalo
Journal:  Mol Oncol       Date:  2013-03-05       Impact factor: 6.603

7.  CDK4: A Key Player in the Cell Cycle, Development, and Cancer.

Authors:  Stacey J Baker; E Premkumar Reddy
Journal:  Genes Cancer       Date:  2012-11

Review 8.  Therapeutic targeting of replicative immortality.

Authors:  Paul Yaswen; Karen L MacKenzie; W Nicol Keith; Patricia Hentosh; Francis Rodier; Jiyue Zhu; Gary L Firestone; Ander Matheu; Amancio Carnero; Alan Bilsland; Tabetha Sundin; Kanya Honoki; Hiromasa Fujii; Alexandros G Georgakilas; Amedeo Amedei; Amr Amin; Bill Helferich; Chandra S Boosani; Gunjan Guha; Maria Rosa Ciriolo; Sophie Chen; Sulma I Mohammed; Asfar S Azmi; Dipita Bhakta; Dorota Halicka; Elena Niccolai; Katia Aquilano; S Salman Ashraf; Somaira Nowsheen; Xujuan Yang
Journal:  Semin Cancer Biol       Date:  2015-04-11       Impact factor: 15.707

Review 9.  Cyclin-Dependent Kinase Inhibitors and Their Therapeutic Potential in Colorectal Cancer Treatment.

Authors:  Oana-Maria Thoma; Markus F Neurath; Maximilian J Waldner
Journal:  Front Pharmacol       Date:  2021-12-21       Impact factor: 5.810

10.  Overexpression of Ras homologous C (RhoC) induces malignant transformation of hepatocytes in vitro and in nude mouse xenografts.

Authors:  Shuli Xie; Mingguang Zhu; Guoyue Lv; Yajun Geng; Guofu Chen; Jian Ma; Guangyi Wang
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.